GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » ROE %

Allurion Technologies (Allurion Technologies) ROE % : Negative Equity% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Allurion Technologies's annualized net income for the quarter that ended in Mar. 2024 was $22.34 Mil. Allurion Technologies's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-68.32 Mil. Therefore, Allurion Technologies's annualized ROE % for the quarter that ended in Mar. 2024 was Negative Equity%.

The historical rank and industry rank for Allurion Technologies's ROE % or its related term are showing as below:

ALUR's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -0.54
* Ranked among companies with meaningful ROE % only.

Allurion Technologies ROE % Historical Data

The historical data trend for Allurion Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies ROE % Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
ROE %
- - -

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - Negative Equity

Competitive Comparison of Allurion Technologies's ROE %

For the Medical Devices subindustry, Allurion Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allurion Technologies's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's ROE % falls into.



Allurion Technologies ROE % Calculation

Allurion Technologies's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-80.607/( (-32.314+-70.487)/ 2 )
=-80.607/-51.4005
=N/A %

Allurion Technologies's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=22.344/( (-70.487+-66.162)/ 2 )
=22.344/-68.3245
=Negative Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Allurion Technologies  (NYSE:ALUR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=22.344/-68.3245
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(22.344 / 37.544)*(37.544 / 65.85)*(65.85 / -68.3245)
=Net Margin %*Asset Turnover*Equity Multiplier
=59.51 %*0.5701*N/A
=ROA %*Equity Multiplier
=33.93 %*N/A
=Negative Equity %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=22.344/-68.3245
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (22.344 / 22.648) * (22.648 / -45.56) * (-45.56 / 37.544) * (37.544 / 65.85) * (65.85 / -68.3245)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9866 * -0.4971 * -121.35 % * 0.5701 * N/A
=Negative Equity %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Allurion Technologies ROE % Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies (Allurion Technologies) Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Website
Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760